Business News

Thermo Fisher Scientific Signs Agreement with Lilly for Companion Diagnostic to be Used with RET Inhibitor

CARLSBAD, Calif., Sept. 9, 2019 /PRNewswire/ — Thermo Fisher Scientific today announced an agreement with Eli Lilly and Company for development of a companion diagnostic that will use the U.S Food and Drug Administration-approved, next-generation sequencing-based Oncomine Dx Target Test to identify certain non-small cell lung cancer (NSCLC) and thyroid …

Read More »

AstraZeneca and Schrödinger Collaborate to Deploy Advanced Computing Technology for Drug Discovery

NEW YORK–(BUSINESS WIRE)–Schrödinger today announced a collaboration with AstraZeneca to deploy Schrödinger’s advanced computing platform to help accelerate drug discovery efforts. Schrödinger’s computational platform combines physics-based modeling and machine learning to enable chemists to predict the potency of a molecule binding to a target protein. This increases the likelihood that, when …

Read More »

Bristol-Myers Squibb and BioMotiv Partner to Form and Fund New Companies to Develop Novel Therapeutics

CLEVELAND & NEW YORK–(BUSINESS WIRE)–BioMotiv, a mission-driven drug development accelerator that advances breakthrough discoveries from research institutions into therapeutics, and Bristol-Myers Squibb Company (NYSE: BMY) today announced a new strategic partnership. The partnership will leverage the strengths of both organizations to develop new and innovative therapies for patients who need …

Read More »

AbbVie and Idera Enter Immuno-Oncology Clinical Research Collaboration

EXTON, Pa., Sept. 04, 2019 (GLOBE NEWSWIRE) — Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) announced today that they have entered into an immuno-oncology clinical research collaboration with AbbVie, a global, research-based biopharmaceutical company.  The purpose of the collaboration is to conduct a clinical study evaluating whether combinations of an OX40 agonist …

Read More »

Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Investigational MEK Inhibitor

Ingelheim, Germany and Mumbai, India – 4 September 2019 – Boehringer Ingelheim and Lupin Limited (Lupin) today announced a licensing, development and commercialization agreement for Lupin’s MEK inhibitor compound (LNP3794) as a potential targeted therapy for patients with difficult-to-treat cancers. The partnership aims to develop Lupin’s lead MEK inhibitor compound in …

Read More »

Vertex to Pay $950 Million to Acquire Stem Cell Biotech Semma Therapeutics

BOSTON & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the company has entered into a definitive agreement under which Vertex will acquire Semma Therapeutics, a privately held biotechnology company pioneering the use of stem cell-derived human islets as a potentially curative treatment for type 1 diabetes, for …

Read More »

Sandoz Announces Global Deal to Commercialize Proposed Biosimilar Natalizumab

Holzkirchen, Germany, September 3, 2019 – Sandoz, a Novartis division and a global leader in biosimilars, today announced that it has entered into a global commercialization agreement for a proposed natalizumab biosimilar. The medicine is in Phase III clinical development for the treatment of relapsing-remitting multiple sclerosis (RRMS). Under the agreement, …

Read More »

RIKEN and Astellas Enter into Worldwide Exclusive Licensing Agreement for Artificial Adjuvant Vector Cell Technology in Oncology

Saitama and Tokyo, September 2, 2019 – RIKEN (President: Hiroshi Matsumoto, Ph.D.) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that they have entered into a worldwide licensing agreement for the research, development and commercialization of cell therapy formulations applying RIKEN’s artificial adjuvant vector …

Read More »

After Phase 3 Failure, AbbVie Discontinues Rova-T Research and Development Program

NORTH CHICAGO, Ill., Aug. 29, 2019 /PRNewswire/ — AbbVie (NYSE: ABBV), a research based global biopharmaceutical company, today announced that MERU, a Phase 3 trial evaluating Rova-T as a first-line maintenance therapy for advanced small-cell lung cancer (SCLC), demonstrated no survival benefit at a pre-planned interim analysis for patients receiving Rova-T as compared with …

Read More »

US Court Backs Sanofi, Regeneron in Amgen Suit for Patents on PCSK9 Drug

PARIS and TARRYTOWN, NY – August 28, 2019 – Sanofi and Regeneron Pharmaceuticals, Inc. announced today that the U.S. District Court for the District of Delaware ruled in their favor and found as a matter of law that Amgen’s asserted patent claims for antibodies targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) …

Read More »